Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:286:198070.
doi: 10.1016/j.virusres.2020.198070. Epub 2020 Jun 20.

COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking

Giuseppe Magro  1
Affiliations
Review

COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking

Giuseppe Magro. Virus Res. 2020 Sep.

Abstract

SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The inflammatory phase includes therapeutic options like Tocilizumab, Anakinra, Baricitinib, Eculizumab, Emapalumab and Heparin. Human clinical trials are starting to show some results, in some cases like that of Remdesivir and corticosteroids these are controversial. Coagulopathy is a common complication in severe cases, inflammation and coagulation are intertwined and cross-talking between these two responses is known to happen. A possible amplification of this cross-talking is suggested to be implicated in the severe cases that show both a cytokine storm and coagulopathy.

Keywords: Baricitinib; COVID-19; Coagulation; Coronavirus; Dexamethasone; Drugs; Eculizumab; Emapalumab; Inflammation; Remdesivir; Ruxolitinib; SARS-CoV-1; SARS-CoV-2; Therapies; Tocilizumab; Treatment.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

References

    1. Al-Salama Z.T. Emapalumab: first global approval. Drugs. 2019;79:99–103. - PubMed
    1. Arabi Y.M., Alothman A., Balkhy H.H. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:81. - PMC - PubMed
    1. Bacharier L.B., Guilbert T.W., Mauger D.T. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015;314:2034–2044. - PMC - PubMed
    1. Begum-Haque S., Sharma A., Kasper I.R. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2008;204:58–65. - PubMed
    1. Bekerman E., Neveu G., Shulla A. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J. Clin. Invest. 2017;127:1338–1352. - PMC - PubMed

MeSH terms

Substances